The exciting potential of immunotherapy for cancer treatment continues its exploration and here, Drug Target Review investigates three of the latest pre-clinical developments in immuno-oncology research.
List view / Grid view
Researchers have shown in mice that macrophages play a role in controlling blood flow and healing following tissue damage.
A combination of checkpoint and small molecule inhibitors showed success at targeting Myc oncogenes in mouse neuroblastoma and melanoma models.
In this article, Dr Lien Lybaert describes how the innate and adaptive immune system work together to produce an effective and durable antitumour response. She explains why the best strategy for personalised cancer therapy is therefore to identify major histocompatibility (MHC) binding epitopes to cover the full antigenic repertoire of…
In this Q&A, Dr Taha Merghoub discusses how a combination of glycolytic-pathway inhibition and immune checkpoint blockade using anti-CTLA-4 in patients with highly glycolytic tumours could present a personalised approach for immuno-oncology.
A new delivery vector using platelets has shown success in pre-clinical trials at delivering photothermal particles and immunostimulators to tumours.
Inhibiting the KDM4A enzyme slowed the growth of head and neck cancer in mouse models, also demonstrating promise to aid immunotherapy.
Researchers have developed a CAR T-cell engineering technique to ensure that only cancer cells are targeted, leaving healthy cells alone in solid tumours.
A team has revealed a function of ADAR1, responsible for RNA editing, discovering an isoform used for cancer growth, making it a drug target.
A team has used two viruses to administer specific tumour components in mice with cancer to stimulate their immune system.
Researchers have shown that inhibiting Treg activation in tumours can provide effective immune responses without autoimmune toxicity.
A new therapeutic approach using the protein IL-21 could optimise the immune system, allowing it to combat HIV.
CAR T cells modified to recognise CEACAM7 were able to eliminate pancreatic ductal adenocarcinoma cells in a late-stage model without toxic effects on healthy tissue.
Researchers have developed a novel CAR T-cell therapy for neuroblastoma which uses gating to limit toxicity and T-cell exhaustion.